PPARGC1B, PPARG coactivator 1 beta, 133522

N. diseases: 102; N. variants: 16
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0678222
Disease: Breast Carcinoma
Breast Carcinoma
0.390 AlteredExpression disease BEFREE We conclude that there is aberrant expression of PPARgamma and its co-activator, PGC-1, in human breast cancer and low levels of these molecules in cancer tissues are associated with poor clinical outcomes. 12866036 2003
CUI: C0678222
Disease: Breast Carcinoma
Breast Carcinoma
0.390 GeneticVariation disease BEFREE The genotype-combination analysis of the associated PPARGC1A Thr612Met variant and the associated PPARGC1B Ala203Pro variant suggests an allele dose-dependent breast cancer risk (P(trend) = 0.0004). 16704985 2006
CUI: C0678222
Disease: Breast Carcinoma
Breast Carcinoma
0.390 Biomarker disease BEFREE Taken together, our results suggest that ERRα and PGC-1β are key players in the etiology of malignant breast cancer by coordinating the transcriptional regulation of genes located in the 17q12 region, a process that also involves interference with the repressive function of ERα on ERBB2 expression. 20961995 2010
CUI: C0678222
Disease: Breast Carcinoma
Breast Carcinoma
0.390 Biomarker disease CTD_human Taken together, our results suggest that ERRα and PGC-1β are key players in the etiology of malignant breast cancer by coordinating the transcriptional regulation of genes located in the 17q12 region, a process that also involves interference with the repressive function of ERα on ERBB2 expression. 20961995 2010
CUI: C0678222
Disease: Breast Carcinoma
Breast Carcinoma
0.390 Biomarker disease BEFREE PGC-1β knockdown in breast cancer cells impaired ERRα signaling and reduced cell proliferation, implicating a functional role for PGC-1β/ERRα in the pathogenesis of breast cancers. 22014575 2011
CUI: C0678222
Disease: Breast Carcinoma
Breast Carcinoma
0.390 Biomarker disease BEFREE Apoptosis induced by PGC-1β in breast cancer cells is mediated by the mTOR pathway. 23877360 2013
CUI: C0678222
Disease: Breast Carcinoma
Breast Carcinoma
0.390 GeneticVariation disease BEFREE PPARγ and PPARGC1B polymorphisms modulate the association between phthalate exposure and BC risk. 23866026 2013
CUI: C0678222
Disease: Breast Carcinoma
Breast Carcinoma
0.390 AlteredExpression disease BEFREE Using quantitative PCR and immunoblotting, we showed that breast cancer cells with HER2-amplification (SKBR-3) have greater expression of PGC-1β as compared to a non-tumorous breast cell (MCF-10A) and higher proliferation rate. 26602383 2016
CUI: C0678222
Disease: Breast Carcinoma
Breast Carcinoma
0.390 GeneticVariation disease BEFREE To evaluate whether the presence of polymorphisms of peroxisome proliferator-activated receptor gamma PPARγ (Pro 1 2Ala) and PPARGC1B (Ala203Pro) modifies the association between the inorganic arsenic (iAs) methylation capacity and breast cancer (BC). 27557380 2016
CUI: C0678222
Disease: Breast Carcinoma
Breast Carcinoma
0.390 AlteredExpression disease BEFREE mRNA and protein expression of PGC-1β and FOXA2 in breast cancer tissues and cell lines were determined by qRT-PCR and Western Blotting, respectively. 31007610 2019